US Patent 8,652,776: Iloperidone Pharmacogenetic Dosing, Claim Scope, and Patent Landscape
US Patent No. 8,652,776 protects a pharmacogenetic dosing method for iloperidone, marketed as Fanapt, in patients with psychotic disorders. The method requires testing both copies of the rs3924426 SNP, classifying the patient according to the genotype, and selecting a lower or higher iloperidone dose based on the presence or absence of a TT genotype. Claim 8 adds QT-prolongation monitoring.
The patent is a method-of-treatment patent rather than a composition, formulation, manufacturing, or product-by-process patent. Its commercial value depends on whether clinicians, laboratories, pharmacies, or generic manufacturers practice or induce practice of the genotype-directed dosing protocol.
What does US Patent 8,652,776 protect?
The patent protects the combined use of:
- A biological-sample test for both copies of rs3924426.
- A genotype-based treatment decision.
- Administration of iloperidone or a pharmaceutically acceptable salt.
- Dose reduction for patients with a TT genotype.
- Dose increase for patients without a TT genotype.
The independent claim does not cover ordinary iloperidone treatment without genetic testing. It also does not cover every pharmacogenetic use of iloperidone. The claim is tied to one specified SNP, rs3924426, and to the particular dosing direction associated with the genotype.
Core claim elements
| Claim element |
Scope |
| Patient |
Human patient |
| Disease |
One or more symptoms of a psychotic disorder |
| Test material |
Biological sample |
| Genetic marker |
Both copies of rs3924426 |
| Treatment agent |
Iloperidone or pharmaceutically acceptable salt |
| TT genotype |
Lower iloperidone dose |
| Non-TT genotype |
Higher iloperidone dose |
| Clinical safety endpoint |
QT prolongation is expressly added in claim 8 |
| Dose ranges |
Claims 2-7 specify lower and higher dose ranges |
The claim uses a treatment decision based on whether the genotype is associated with increased QT prolongation. The operative genotype distinction is TT versus non-TT.
How do claims 1 through 8 differ?
Claim 1 is the broadest claim and contains the principal infringement limitations. Claims 2 through 7 narrow the doses. Claim 8 adds patient monitoring.
| Claim |
Additional limitation |
| 1 |
Genotype-guided iloperidone dosing using rs3924426 |
| 2 |
Lower effective amount of about 2-24 mg/day |
| 3 |
Lower effective amount of about 5-20 mg/day |
| 4 |
Lower effective amount of about 10-15 mg/day |
| 5 |
Increased amount of about 24-50 mg/day |
| 6 |
Increased amount of about 30-50 mg/day |
| 7 |
Increased amount of about 40-50 mg/day |
| 8 |
Monitoring the patient for QT prolongation |
The dependent claims create nested ranges. A regimen of 10-15 mg/day falls within claims 2, 3 and 4 if all other limitations are met. A 40-50 mg/day regimen falls within claims 5, 6 and 7.
What is the practical meaning of the TT and non-TT dosing branches?
The patent divides patients into two treatment groups.
| Genotype |
Claimed treatment |
| TT at rs3924426 |
Administer less iloperidone than would be given to a non-TT patient |
| Non-TT genotype |
Administer more iloperidone than would be given to a TT patient |
For TT patients, the lower-dose claims overlap the FDA-approved Fanapt dosing range. The Fanapt label generally describes a titration schedule leading to a recommended range of 12-24 mg/day for schizophrenia, with dose adjustments for certain metabolic conditions and drug interactions (FDA, 2024).
The higher-dose claims reach 24-50 mg/day, including ranges above the labeled maximum daily dose for schizophrenia. That distinction matters commercially. Claims 5-7 may be more difficult to practice under routine U.S. labeling unless a physician uses an off-label dose or a future label expands the approved range.
The claims do not require that the patient actually develop QT prolongation. They require a genotype-based dose decision tied to QT-prolongation risk. Claim 8 separately requires monitoring for QT prolongation.
What is the patent’s technical scope?
The patent sits at the intersection of pharmacogenomics, antipsychotic treatment, and cardiac safety.
Genetic-testing requirement
Claim 1 requires determining the genotype in both copies of the SNP locus. A test reporting only a single allele, an incomplete genotype, or a broader genetic risk score would not literally satisfy this limitation unless the result establishes the two-copy genotype.
Potential testing formats include:
- Genotyping from blood, saliva, buccal cells, or another biological sample.
- Laboratory-developed tests.
- Multiplex pharmacogenetic panels.
- Sequencing or allele-specific assays that identify rs3924426.
The claim does not require a particular testing platform, laboratory, assay chemistry, or reporting format.
Drug requirement
The active treatment must be iloperidone or a pharmaceutically acceptable salt. The patent does not claim unrelated antipsychotics, generic QT-risk stratification, or a dose algorithm detached from iloperidone.
Disease requirement
The claim refers to symptoms of a psychotic disorder. It is broader than a claim limited to schizophrenia, although schizophrenia is the principal FDA-approved indication for Fanapt. A treatment directed to another psychotic disorder could fall within the language if the remaining claim elements are satisfied.
Dose-comparison requirement
The claim requires a relative dose comparison:
- TT patients receive less than the amount given to a patient without TT.
- Non-TT patients receive more than the amount given to a patient with TT.
This relative comparison is important. A fixed dose given to every patient, without genotype-based differentiation, presents a weaker infringement case even if the fixed dose falls within one of the numerical ranges.
What is the Orange Book status of US 8,652,776?
US 8,652,776 is associated with the Fanapt iloperidone patent estate and has been treated as a listed method-of-use patent in the U.S. regulatory framework. Orange Book listing status can affect ANDA certification obligations and the timing of generic approval under the Hatch-Waxman Act (FDA, 2024a).
A listed method patent may be addressed by an ANDA applicant through:
- Paragraph III certification, accepting approval after patent expiration.
- Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.
- A section viii statement, where the applicant omits the patented indication or use from its proposed labeling.
The usefulness of a section viii strategy depends on whether the proposed generic labeling, prescribing information, pharmacy substitution pathway, and distribution materials exclude the genotype-directed use.
When does US Patent 8,652,776 lose exclusivity?
The patent has a 2006 priority basis and a nominal twenty-year term extending into 2027. The relevant U.S. patent record should be read together with the USPTO term-adjustment calculation and any Orange Book-listed expiration information. The publicly associated term is in June 2027 after patent-term adjustment.
The patent’s practical exclusivity may end earlier for a particular generic product if the applicant successfully avoids the claimed use through labeling or defeats the patent in litigation. It may also be commercially limited if the genotype-directed method is not routinely used in clinical practice.
FDA regulatory exclusivity and patent exclusivity are separate:
| Exclusivity type |
Relevance to Fanapt |
| New chemical entity exclusivity |
Expired |
| Patent exclusivity |
Extends into 2027 for the relevant patent estate |
| Pediatric exclusivity |
Must be confirmed in current FDA records |
| Orphan exclusivity |
Not the principal protection for Fanapt schizophrenia use |
| Method-of-use protection |
Central to US 8,652,776 |
Which companies are challenging the iloperidone patent estate?
Generic applicants seeking approval for iloperidone can challenge listed Fanapt patents through Paragraph IV certifications. Public Hatch-Waxman activity involving Vanda’s Fanapt patent estate has included litigation against generic applicants, including Teva-related entities.
The relevant litigation analysis must distinguish between:
- Litigation specifically naming US 8,652,776.
- Litigation involving other Fanapt patents.
- Settlements that resolve a specific ANDA.
- FDA approval timing for the generic product.
- Whether the generic label includes or omits the claimed pharmacogenetic use.
A Paragraph IV challenge would likely focus on claim construction, written description, enablement, obviousness, anticipation, and infringement. A generic applicant may argue that its label does not encourage rs3924426 testing or genotype-directed iloperidone dosing.
What patent litigation issues are most important?
Infringement and induced infringement
The most important enforcement issue is divided infringement. The method requires genetic testing and treatment. Different actors may perform different steps:
- A laboratory determines the genotype.
- A physician interprets the result and selects the dose.
- A pharmacy dispenses iloperidone.
- The patient takes the drug.
A patent owner would need to establish direct infringement by a single actor or inducement based on instructions, labeling, clinical protocols, or other evidence linking the testing and dosing steps.
Label-based infringement
An ANDA label that expressly recommends rs3924426 testing, lower dosing for TT patients, higher dosing for non-TT patients, or QT monitoring would create a stronger infringement theory.
A label that omits the patented use may support a section viii defense. The analysis would depend on whether the remaining label, promotional materials, dosing instructions, or standard clinical use still encourage the patented regimen.
Validity
The principal validity questions are:
- Whether the genotype-dose-QT relationship was adequately supported by the specification.
- Whether the claimed dosing method was predictable from prior pharmacogenetic or iloperidone data.
- Whether the claims adequately describe the full scope of TT and non-TT treatment.
- Whether the claimed association was statistically and clinically established.
- Whether the claims are patent-eligible under the diagnostic-method framework.
The claims are stronger than a bare claim to identifying a natural correlation because they recite a concrete treatment step: administering a specified drug at a genotype-dependent dose. The Federal Circuit has treated treatment claims differently from claims directed only to observing or reporting a natural phenomenon, although eligibility depends on the precise claim construction and record.
How strong is the patent estate for iloperidone?
US 8,652,776 is strategically important but narrow in technology and potentially limited in clinical adoption.
| Strength factor |
Assessment |
| Claim specificity |
High; the claim identifies one SNP and a precise treatment decision |
| Product coverage |
Limited to iloperidone |
| Formulation coverage |
None apparent from the supplied claims |
| Manufacturing coverage |
None apparent from the supplied claims |
| Diagnostic coverage |
Limited to use of rs3924426 in treatment |
| Label leverage |
Potentially meaningful if genotype-guided dosing appears in labeling |
| Clinical adoption dependence |
High |
| Generic design-around potential |
Meaningful through label omission and non-genotyped dosing |
| Remaining term |
Extends into 2027 |
| Biosimilar relevance |
None; iloperidone is a small molecule |
The patent does not block manufacture or sale of ordinary iloperidone tablets by itself. It targets a particular clinical-use pathway.
What formulations are protected by US 8,652,776?
The supplied claims do not contain formulation limitations. They do not require:
- Immediate-release or extended-release tablets.
- A particular excipient.
- A specific polymorph.
- A controlled-release matrix.
- A particular salt or particle size.
- A specific packaging configuration.
- A dosage form other than administration of iloperidone or its pharmaceutically acceptable salt.
Formulation protection must be assessed in separate Fanapt patents, including composition, solid-state, process, or dosage-form patents. US 8,652,776 should not be treated as a formulation patent.
Does the patent create biosimilar risk?
No. Iloperidone is a small-molecule drug approved through an NDA. Generic applicants use the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.
The competitive risks are therefore:
- ANDA approval after listed-patent resolution.
- Paragraph IV litigation.
- Section viii label carve-outs.
- Authorized-generic or settlement arrangements.
- Prescriber adoption of genotype-guided dosing.
What licensing deals affect the patent?
Vanda Pharmaceuticals is the principal commercial holder associated with Fanapt and its patent estate. A material license, assignment, or settlement affecting US 8,652,776 would be reflected in USPTO assignment records, court filings, FDA patent records, or ANDA settlement disclosures.
The patent itself does not establish a license. No license can be inferred solely from the claims, ownership history, or commercial distribution of iloperidone.
How does US 8,652,776 compare with ordinary Fanapt patent protection?
| Protection type |
Covered by US 8,652,776? |
Commercial effect |
| Iloperidone molecule |
No |
Requires separate compound patent |
| Iloperidone salt |
Only as treatment agent |
Does not broadly block salt manufacture |
| Tablet formulation |
No |
Requires formulation patent |
| Manufacturing process |
No |
Requires process patent |
| Schizophrenia treatment |
Yes, but only with genotype-directed dosing |
Can delay or complicate generic use |
| rs3924426 testing |
Only when linked to claimed treatment |
Does not broadly control diagnostic testing |
| QT monitoring |
Yes, under claim 8 |
Adds a monitoring limitation |
| Generic iloperidone sale |
Not automatically blocked |
Depends on label, use, and patent status |
What generic launch scenarios exist?
Scenario 1: Full-label generic launch after patent expiry
A generic applicant retains all relevant iloperidone indications and launches after the listed patent estate expires or is held invalid. This is the cleanest launch path.
Scenario 2: Paragraph IV challenge
The applicant certifies that US 8,652,776 is invalid, unenforceable, or not infringed. Litigation may trigger the Hatch-Waxman thirty-month stay, subject to statutory exceptions and court rulings.
Scenario 3: Section viii carve-out
The applicant omits the genotype-directed dosing language from its label. This approach is more attractive if the proposed generic label does not instruct physicians to test rs3924426 or adjust iloperidone dose according to TT status.
Scenario 4: Non-practicing clinical use
The generic launches without any genotype-based instructions. The patent remains formally enforceable, but its market leverage is reduced if routine prescribing does not implement the patented method.
What is the geographic coverage?
US 8,652,776 is a United States patent. It does not create rights in Europe, Japan, Canada, or other jurisdictions.
International protection would require separate national or regional patents claiming the same rs3924426-guided iloperidone method. Freedom-to-operate conclusions outside the United States cannot be drawn from this patent number.
Key Takeaways
- US 8,652,776 is a pharmacogenetic method patent for iloperidone.
- Its central limitation is testing both copies of rs3924426 and adjusting iloperidone dose based on TT versus non-TT status.
- Claims 2-4 cover lower doses from about 2-24 mg/day, with the narrowest range at 10-15 mg/day.
- Claims 5-7 cover increased doses from about 24-50 mg/day.
- Claim 8 requires QT-prolongation monitoring.
- The patent does not claim iloperidone formulations, manufacturing methods, or the active ingredient itself.
- The patent estate has a term extending into June 2027 under the associated U.S. patent-term calculation.
- Generic risk centers on Paragraph IV validity challenges, section viii label carve-outs, and proof of induced infringement.
- The patent has no biosimilar significance because iloperidone is a small molecule.
- Its commercial value depends heavily on whether rs3924426 testing and genotype-directed dosing are included in FDA labeling or routine medical practice.
FAQs
Is rs3924426 testing required for every Fanapt prescription?
No. US 8,652,776 claims a particular genotype-guided treatment method. It does not impose a general regulatory requirement that every patient receiving iloperidone undergo rs3924426 testing.
Does US 8,652,776 cover iloperidone for schizophrenia at any dose?
No. The claim requires genetic testing and a dose decision based on TT versus non-TT genotype. Ordinary, non-genotype-directed iloperidone treatment falls outside the core claim as provided.
Can a generic manufacturer sell iloperidone before June 2027?
Potentially, depending on patent certifications, litigation outcomes, settlement terms, label carve-outs, and other listed Fanapt patents. The patent does not automatically prevent every generic sale before its expiration.
Are doses above 24 mg/day FDA-approved for Fanapt?
The standard FDA labeling for schizophrenia identifies a maximum daily dose of 24 mg/day. The 24-50 mg/day ranges in claims 5-7 therefore extend above the ordinary labeled dosing range.
Does the patent cover a commercial genetic test for rs3924426?
Not by itself. The supplied claims require use of the genotype determination in the claimed iloperidone treatment method. A test sold independently, without that treatment use, raises a different infringement analysis.
References
-
U.S. Patent No. 8,652,776. (2014). Methods of treating psychotic disorders. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Fanapt (iloperidone) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug product patent and exclusivity information. FDA.
-
United States Patent and Trademark Office. (2024). Patent term adjustment and patent assignment records for U.S. Patent No. 8,652,776. USPTO.
-
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).